SCHEMBL10650165

SCHEMBL10650165

Oc1cnc2ccsc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
MAP4K4 O95819 1/20 0.36
CDK8 P49336 1/20 0.36
CLK2 P49760 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CDK5 Q00535 1/20 0.36
ACVR1 Q04771 1/20 0.36
ROCK1 Q13464 1/20 0.36
DYRK1A Q13627 1/20 0.36
LRRK2 Q5S007 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21530704 0.79 KDM4E (0.39) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL6605559 0.76 KDM4E (0.37) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL7220036 0.75 MAPT (0.39) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL10650166 0.75 KDM4E (0.39) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL19117783 0.75 KDM4E (0.39) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL12113792 0.75 KDM4E (0.53) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL16538034 0.75 HTT (0.39) KDM4ETDP1HTTMAPTALDH1A1
SCHEMBL30895185 0.73 NPC1 (0.57) KDM4ETDP1ALDH1A1HPGDL3MBTL1
SCHEMBL843647 0.73 NPC1 (0.57) KDM4ETDP1ALDH1A1HPGDL3MBTL1
SCHEMBL22079498 0.72 CYP2A6 (0.47) KDM4ETDP1HTTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2895488-B1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2024-12-11 EP disclosed
WO-2024238406-A1 FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF FRONTIER MEDICINES CORPORATION (US) 2024-11-21 WO disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LIMITED (KY) 2020-04-30 US disclosed
CN-105189505-A Tricyclic gyrase inhibitors as antibacterial agents TRIUS THERAPEUTICS INC 2015-12-23 CN disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
EP-2895488-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS Trius Therapeutics, Inc. (US) 2015-07-22 EP disclosed
WO-2014043272-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS TRIUS THERAPEUTICS INC. (US) 2014-03-20 WO disclosed
WO-2014043272-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS TRIUS THERAPEUTICS INC. (US) 2014-03-20 WO disclosed
EP-0271273-A2 Thieno-and furopyridine sulfonamides MERCK & CO. INC. (US) 1988-06-15 EP disclosed
US-4731368-A Thienopyridine sulfonamides and their ophthalmological formulation MERCK & CO., INC. (US) 1988-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS TOP1, TOP2A, TOP2B KDM4E 2335/4885TDP1 8/4885HTT 4315/4885
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 KDM4E 1912/4885TDP1 2436/4885HTT 4407/4885
US-10865216-B2 Tricyclic Gyrase inhibitors TOP1, TOP2A, TOP2B KDM4E 2335/4885TDP1 8/4885HTT 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.